Claris Bio, based in Jersey City, NJ, was founded by a group of experienced biopharma industry executives and experts in ophthalmology. The company’s foundational intellectual property is based on work done at the Massachusetts Eye and Ear Infirmary by Dr. Reza Dana, MD, MSc, MPH, Claes Dohlman Chair in Ophthalmology, Harvard Medical School and Senior Scientist and Director of Cornea at Mass Eye and Ear and Dr. Sunil Chauhan, DVM, PhD, Principal Investigator and Associate Professor, Mass Eye and Ear, Harvard Medical School. Claris’ lead program, CSB-001 Ophthalmic Solution 0.1%, brings a topical ocular biologic solution of oremepermin-α, a molecule with the potential to restore structural and functional corneal integrity, to eyes with neurotrophic keratopathy (NK). For more information about Claris, please visit www.clarisbio.com.
Company Details
- Address
- Jersey City, New Jersey, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://clarisbio.com/
- HQ
- Jersey City, New Jersey
Claris Bio Questions
Claris Bio's website is https://clarisbio.com/
Claris Bio's LinkedIn profile is https://www.linkedin.com/company/claris-bio
Claris Bio's industry is
Biotechnology Research
Claris Bio's top competitors are
Calluna Pharma,
Radionetics Oncology,
Synnovation Therapeutics,
Atai Life Sciences,
Cour Pharma,
Moonwalk Biosciences,
Hi-Bio: A Biogen Company,
Accent Therapeutics, Inc.,
Tr1x,
Lykos Therapeutics.
Claris Bio's categories are Biotechnology Research
